Mitochondria-Targeted Antibiotics toward Drug Resistant TNBC

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Drug resistance poses a significant challenge in cancer therapy.
• Mitochondria are key regulators of cell survival and death via reactive oxygen species (ROS).
• Targeting mitochondria offers a strategy to enhance cancer treatment efficacy and overcome resistance.

Purpose of the Study:

• To introduce and evaluate a novel mitochondria-targeted antibiotic, compound 1 (CFX-TPP+), for combating drug-resistant triple-negative breast cancer (TNBC).
• To assess the stability and in vitro efficacy of compound 1 against TNBC cells.

Main Methods:

• Synthesis and characterization of compound 1 (CFX-TPP+), a mitochondria-targeted antibiotic with an amide functional unit.
• Assessment of compound 1's stability in blood plasma compared to an ester-containing analog.
• Evaluation of compound 1's cytotoxicity against drug-resistant TNBC cells (MDA-MB-231).
• Analysis of ROS generation, mitochondrial oxidative stress, and downstream apoptotic signaling pathways.

Main Results:

• Compound 1 demonstrated superior stability in blood plasma compared to its ester counterpart.
• Compound 1 exhibited significant cytotoxicity against drug-resistant TNBC cells.
• Treatment with compound 1 led to enhanced ROS generation and increased mitochondrial oxidative stress.
• Compound 1 induced mitochondria-mediated apoptosis, upregulated BAX, and downregulated genes involved in mitochondrial biogenesis.

Conclusions:

• Compound 1 (CFX-TPP+) is a stable and effective mitochondria-targeted agent against drug-resistant TNBC.
• This approach shows potential for overcoming drug resistance and achieving disease remission in TNBC.
• Targeting mitochondrial ROS offers a promising strategy for novel cancer therapeutics.